Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK (no. 4) Limited

Viiv Healthcare UK Limited

Jacob Swidorski

Alicia Regueiro-Ren

Nicholas A Meanwell

Sing-Yuen Sit

Jie Chen

Zheng Liu

Yan Chen

Ny Sin

Richard A Hartz

Brian Lee Venables

Tao Wang

Zhongxing Zhang

David J Carini

John F Kadow

Lawrence G Hamann

Zhiwei Yin

Li Xu

Yasutsugu Ueda

Ying Han

Brett R Beno

Barry L Johnson

Ira B Dicker

Beata Nowicka-Sans

Ramakanth Sarabu

Satheesh Kesavan Nair

Manoranjan Panda

Prasada Rao Jalagam

Wenying Li

Animesh Goswami

David S Yoon

Zhiwei Guo

Nicolas A Meanwell

Thomas P Tully

Alicia Regueiro-ren

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of galectin-3

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

Azadecalin derivatives as inhibitors of human immunodeficiency virus replication

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I and II: These compounds are useful for the treatment of HIV and AIDS.

Oxolupene derivatives

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

Betulinic acid derivatives with HIV maturation inhibitory activity

Extended betulinic acid analogs

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: a compound of Formula I     The compounds are useful for the treatment of HIV and AIDS.

C-3 alkyl and alkenyl modified betulinic acid derivatives

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: wherein X can be a Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Coxaspirocycloalkyl, or Coxaspirocycloalkenyl ring. These compounds are useful for the treatment of HIV and AIDS.

C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Growing community of inventors

Southington, CT, United States of America

Jacob Swidorski